A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
A phase 2 trial of AK146D1, Ivonescimab, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.
Overview
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT07669779 by Akeso, with 348 participants planned, started 2026-07-10 and due to reach its primary completion in 2027-08-30. Interventions recorded: AK146D1 for injection, AK112 Injection, Platinum chemotherapy, Osimertinib. Conditions listed: Advanced Non Small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
- TrialA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.